Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIMID: Filgotinib for Rare IMIDs
NCT06285539Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of filgotinib in Behçet's disease (BD), idiopathic inflammatory myopathy (IIM), IgG4-related disease (IgG4-RD). Started Mar 2024; status: recruiting.
02
Drugs
filgotinib
03
Conditions
Behçet's disease (BD)idiopathic inflammatory myopathy (IIM)IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT06285539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285539.